JWA
ZNTL icon

JFS Wealth Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

JFS Wealth Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed – – 1963
2022
Q1 		$0 Buy
+1
New +$54 ﹤0.01% 1995

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

JFS Wealth Advisors's ZNTL Position: Q2 2022 in Review

JFS Wealth Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2022, closing a stake of 1 share.

JFS Wealth Advisors first reported a position in ZNTL in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 122 funds tracked by Wall St. Rank hold ZNTL as of Q2 2022.

  • JFS Wealth Advisors reported no remaining Zentalis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • JFS Wealth Advisors sold 1 Zentalis Pharmaceuticals share in Q2 2022.
  • JFS Wealth Advisors first reported a position in Zentalis Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • JFS Wealth Advisors's Zentalis Pharmaceuticals position peaked at $0 in Q1 2022.
  • 122 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2022.

Based on JFS Wealth Advisors's 13F filing for Q2 2022, filed 2 Aug 2022.